China Defends Industrial Policy Ahead of Key U.S. and EU Trade Talks 
Gulf Shipping Traffic Steady as U.S.-Iran Talks Remain Uncertain 
US Stock Futures Rise as Trump Signals Iran Talks, Markets Await SpaceX Earnings and Jobs Data 
U.S., Iran, Oman Near Interim Deal to Reopen Strait of Hormuz Amid Ceasefire Efforts 
Oil Prices Extend Three-Day Decline as Hopes Rise for U.S.-Iran Strait of Hormuz Deal 
Jetstar to Charge for Overhead Cabin Bags From February 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
RBI Holds Repo Rate at 5.25% as Inflation Risks and Global Uncertainty Persist 
Gold Prices Rise as Trump Delays Iran Strike, Oil Slumps 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
KOSPI Drops Nearly 5% as Samsung, SK Hynix Lead AI Stock Selloff 
25 Democratic-Led States Sue Trump Administration Over New Global Tariffs 
Asian Currencies Rise as Dollar Stays Near Six-Week Low, RBI Holds Rates Steady 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Eli Lilly and Company has acquired biopharmaceutical firm Dice Therapeutics for $2.4 billion, fortifying its position in immune-related disease treatments. The strategic move expands Lilly's portfolio with Dice's cutting-edge oral drugs for autoimmune conditions.
Eli Lilly said that the deal with Dice Therapeutics is worth $2.4 billion, and it was agreed that it would pay $48 per share in cash for the purchase. This is equivalent to a 40% premium where the latter's shares closed last Friday.
As per CNBC, the buyout is expected to be completed within the third quarter of this year. With the announcement of the negotiations, the stock price of Eli Lilly reportedly shot up by more than one percent in the early morning trading today. Dice Therapeutics' share price also increased by more than 37%.
Dice Therapeutics is known to use proprietary technology to create new oral drug treatments for various autoimmune diseases. These are illnesses wherein the immune system attacks the person's own cells instead of protecting them as they should.
Currently, there are over 100 known kinds of autoimmune diseases, and the most well-known are lupus, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. The San Francisco-based pharma company is a leading drugmaker to help treat such conditions. Aside from these medications, it is also in the middle of developing another drug for psoriasis which is an immune-related skin condition.
"In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases," Lilly USA's executive vice president, president of Immunology, and chief customer officer, Patrik Jonsson, said in a press release. "We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs."
Dice Therapuetics' CEO, Kevin Judice, Ph.D., further said, "We are eager to see our pipeline, including our oral IL-17 inhibitors, DC-806 and DC-853, benefit from Lilly's resources and global reach and I'm excited by the prospect of watching these two talented teams in a united quest for scientific innovation."
Photo by: Eli Lilly Press Release
